Seattle Genetics
ADCETRIS
Manufacturer:
Seattle Genetics
Name:
ADCETRIS
HCPCS Code Descriptor:
Injection, brentuximab vedotin, 1 mg
Category:
J Code
HCPCS:
J9042
NDC(s):
51144-0050-01
Primary Type:
Oncology
Generic/Specialty Status:
Single-Source
Route of Administration:
Intravenous
Potential NDC Listing Errors:
Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.
About:
ADCETRIS is an Oncology drug manufactured by Seattle Genetics and administered via the Intravenous route of administration. The J Code: J9042 is aligned to the drug ADCETRIS.
Adcetris is an antibody-drug conjugate that targets tumors expressing the CD30 antigen, a common tumor protein in certain types of lymphoma. Adcetris is administered as an intravenous infusion with the dosage and frequency of treatment dependent on the type and stage of the cancer being treated. Adcetris is co-marketed by both Millennium Pharmaceuticals and Seattle Genetics.
Access Pricing and More By Registering
HCPCS Added Date:
1/1/13
HCPCS Effective Date:
1/1/13
HCPCS Short Description:
Brentuximab vedotin inj
Billing and Coding Guide:
https://www.seagensecure.com/assets/pdfs/Adcetris/ADCETRIS_Coding_and_Billing_Guide.pdf
Patient Assistance:
https://www.seagensecure.com/patient/adcetris